

August 13, 2024

# Asymptomatic Bacteriuria in Pregnancy

Michela Blain, MD, MPH



## Outline

- Case
- Background
- When & why do we screen & treat?
- Treatment



- Case
- Background
- When & why do we screen & treat?
- Treatment





A 28yo woman saw you in clinic yesterday for her first prenatal visit after a recent positive pregnancy test. She was found to be 10 weeks pregnant. Among your initial screening labs, her urine culture returned positive with >100,000 col/mL E coli. At your visit, her vitals were normal and on ROS, she reported no urinary symptoms.



After seeing her urine culture, what do you recommend?

- **A.** This is asymptomatic bacteriuria recommend no treatment.
- **B.** Nitrofurantoin 100mg BID
- C. Amoxicillin-clavulanate 875-125mg BID
- **D.** Ciprofloxacin 500mg BID
- **E.** IV Ceftriaxone 1g QD
- **F.** B or C
- **G.** B or D



- Case
- Background
- When & why do we screen & treat?
- Treatment



## Asymptomatic Bacteriuria (ASB)

- UTIs vs ASB
- YAY pregnancy this is one scenario where we treat regardless!
  - IDSA & ACOG guidelines
- But wait... why is that? And should we?



## Diagnosis

- Asymptomatic Bacteriuria
  - >100,000 CFU/mL
  - No symptoms
- Common organisms needing treatment:
  - E coli, Proteus, Klebsiella, GBS
- Normal vulvovaginal flora should not be treated:
  - Lactobacilli, Corynebacteria, coagulase negative Staphylococcus
- Lower colony counts do not require treatment
  - If GBS seen, note for delivery prophylaxis



#### Prevalence

• Prevalence of ASB in pregnant women 2 – 9.5 %

Population	Prevalence of ASB
Pregnant women	2 – 9.5 %
Premenopausal women	1 – 5%
Women > 70y, community dwelling	10 – 16%
>70y, in long term care facility	15 – 50%

### Why higher rates in pregnancy?

- Multifactorial
  - Mechanical compression of ureters by uterus 

     Increased residual volume and urinary stasis
    - Higher volume + Stasis → ↑ ASB
  - Progesterone 

    Ureteral dilation
    - Bacterial colonization + Dilation → Vesicoureteral reflux →
       ↑ Risk of ascending infection
  - Relative immunosuppression of pregnancy



- Case
- Background
- When & why do we screen & treat?
- Treatment



#### When & how to screen

- Screen: "early" in pregnancy
  - Pyelonephritis is most prevalent in the 2<sup>nd</sup> trimester but a significant proportion of cases happen in the 1<sup>st</sup> trimester
- Clean catch counseling
  - Local cleansing of urethral meatus + surrounding mucosa
  - Spread the labia
  - Midstream urine catch







# Why screen & treat?

- Asymptomatic bacteriuria
  - Progression to UTI and pyelonephritis
  - Increase rates of preterm birth and low birthweight babies
  - Additional risks of pyelo in pregnancy: sepsis, DIC, ARDS
- Cochrane Review 2019:
  - 14 RCTs (mostly from the 1960s & 70s) showed ASB screening/tx led to decrease in pyelonephritis during pregnancy
  - At that time, 20-35% of women with untreated ASB went on to develop pyelo during pregnancy
    - Treatment reduced the risk by 80%
- More recent randomized studies show only 2.2-2.9% pyelonephritis rate in untreated group



# Why screen & treat?

- Netherlands: Does not routinely screen for ASB in pregnancy
  - 2015 study: 4,283 pregnant women
    - ASB women: randomized to placebo or nitrofurantoin BID x 5 days
    - Frequency of pyelo in women with:
      - No bacteriuria 0.6% (24/4035)
      - Untreated ASB 2.4% (5/208)
      - Treated ASB 0% (0/40)
    - No significant difference in low birth weight or preterm births between the groups
  - Limited absolute risk of pyelonephritis (much lower than previously reported); No increased risk of preterm birth or LBW infant between groups
- Screen all pregnancies vs only higher risk?



# Why screen & treat?

- New contemporary baseline rate is lower even without screening/tx
- Still, studies show consistent association with treating and decreases in pyelonephritis, so screening and treatment are still recommended
  - Risks of serious adverse effects of abx vs reduction in pyelo and preterm birth
- So: Screen all pregnant patients vs only higher risk?
  - For now: Screen during each pregnancy
  - Need better data



- Case
- Background
- When & why do we screen & treat?
- Treatment



# **Treatment of ASB**

Trimester:	Treatment Options:	Notes:
All Trimesters:	Amoxicillin	
	Amoxicillin-clavulanate	
	Cephalexin	
	Cefpodoxime	
	Fosfomycin	
2T or Early 3T:	Nitrofurantoin	<ul> <li>Small studies with associated birth defects → Avoid 1T</li> <li>Risk of hemolytic anemia in G6PD def → Avoid near term</li> </ul>
	TMP-SMX	<ul> <li>TMP is a folic acid antagonist         → Avoid 1T</li> <li>SMX theoretical risk for kernicterus → Avoid near term</li> </ul>

#### **Treatment of ASB**

- Antibiotics to avoid during pregnancy:
  - Aminoglycosides risk of ototoxicity in fetus
  - Doxycycline risk of hepatoxicity, adverse effects on fetal bone/teeth (rare exceptions)
  - Fluoroquinolones toxic to developing cartilage in fetus
  - Macrolides associated with miscarriages



#### **Treatment**

- Duration
  - 4-7 days
  - 2015 Cochrane review
    - Compared single dose to short course (4-7 days) → trend toward lower rates of clearance of bacteriuria with single dose regimens
  - 2009 Review
    - 7 days of nitrofurantoin better than 1 in preventing LBW
    - No difference in pyelonephritis or preterm delivery



After seeing her urine culture, what do you recommend?

- **A.** This is asymptomatic bacteriuria recommend no treatment.
- **B.** Nitrofurantoin 100mg BID
- C. Amoxicillin-clavulanate 875-125mg BID
- **D.** Ciprofloxacin 500mg BID
- **E.** IV Ceftriaxone 1g QD
- **F.** B or C
- **G.** B or D



After seeing her urine culture, what do you recommend?

- A. This is asymptomatic bacteriuria recommend no treatment. → Treat during pregnancy
- **B.** Nitrofurantoin 100mg BID  $\rightarrow$  Avoid in first trimester
- C. Amoxicillin-clavulanate 875-125mg BID
- **D.** Ciprofloxacin 500mg BID → Avoid in pregnancy
- **E.** IV Ceftriaxone 1g QD → Avoid IV when possible
- F. B or C
- G. Bor D



## Summary

Screen and treat ASB early in pregnancy

 Nontreatment may become increasingly acceptable for low-risk individuals as more data becomes available

• Duration: 4-7 days